New expert recommendations aim to improve detection and care of lung disease in people with rheumatoid arthritis
· Medical Xpressedited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
A new international expert consensus statement published in The Lancet Respiratory Medicine provides guidance for doctors on how to identify, monitor and treat a serious lung complication that affects many people living with rheumatoid arthritis (RA).
RA is best known as a disease that causes joint pain and inflammation, but it can also affect the lungs. One of the most serious complications is rheumatoid arthritis-associated interstitial lung disease (RA-ILD), a condition that causes scarring and inflammation in the lungs, making it harder to breathe and reducing quality of life.
"Rheumatoid arthritis doesn't just affect the joints—it can also affect the lungs in ways that can significantly affect a person's health and quality of life," said Joshua Solomon, MD, lead author of the study and director of interstitial lung disease at National Jewish Health.
"These recommendations provide practical guidance to help clinicians identify lung disease earlier, monitor patients more effectively and determine when treatment may be appropriate."
Because there has been little agreement among medical experts about when patients should be screened for lung disease, how often they should be monitored and when treatment should begin, an international panel of specialists developed a set of consensus recommendations to help guide patient care.
The experts reviewed the available evidence and identified key risk factors that may increase the likelihood of developing RA-ILD. They also outlined recommendations for screening patients with RA who may be at higher risk, as well as approaches for monitoring disease progression and selecting treatment options.
The consensus statement emphasizes a team-based approach involving rheumatologists, pulmonologists and other specialists to help ensure patients receive comprehensive care.
The recommendations are intended to help clinicians make informed decisions in situations where high-quality clinical trial data is limited. Researchers hope the guidance will lead to earlier diagnosis, more consistent care and improved outcomes for people living with RA-related lung disease.
Publication details
Joshua J Solomon et al, Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment—an expert group consensus statement, The Lancet Respiratory Medicine (2026). DOI: 10.1016/s2213-2600(26)00094-9
Journal information: Lancet Respiratory Medicine
Key medical concepts
Rheumatoid ArthritisRisk Factors
Clinical categories
RheumatologyPulmonary medicineCommon illnesses & Prevention Provided by National Jewish Health Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: New expert recommendations aim to improve detection and care of lung disease in people with rheumatoid arthritis (2026, July 2) retrieved 2 July 2026 from https://medicalxpress.com/news/2026-07-expert-aim-lung-disease-people.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.